palforzia
aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.
stimufend
fresenius kabi deutschland gmbh - pegfilgrastim - neutropenija - Иммуностимуляторы, , колониестимулирующие faktori - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).
xofigo
bayer ag - radium (223ra) dichloride - prostatske neoplazme - terapeutski radiofarmaceutski pripravci - xofigo je indiciran za liječenje odraslih osoba s karcinomom prostate otpornih na kastriranje, simptomatskim koštanim metastazama i bez poznatih visceralnih metastaza.
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denga - cjepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 i 4. korištenje dengvaxia moraju biti u skladu sa službenim preporukama.
phesgo
roche registration gmbh - pertuzumab, trastuzumab - neoplazme dojki - antineoplastična sredstva - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
ponvory
janssen-cilag international n.v. - ponesimod - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastična sredstva - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
rybrevant
janssen-cilag international n.v. - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
benlysta
glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemski - imunosupresivi - benlysta navodi kao dopuna terapije kod pacijenata u dobi od 5 i više godina uz aktivnu, pozitivnu аутоантитела sistemski eritemski lupus (sle) s visokim stupnjem aktivnosti bolesti (e. pozitivna anti-ova dnk i niska razina komplementa), bez obzira na standardnu terapiju. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
bosulif
pfizer europe ma eeig - bosutinib (kao monohidrat) - leukemija, mieloid - antineoplastic agents, protein kinase inhibitors - bosulif indiciran za liječenje odraslih bolesnika s prvi put prijavljene kronične faze (cp) kromosoma-pozitivnim philadelphia kronične миелогенной leukemije (ph+ kml). srijeda, ubrzana faza (ap), i бластном (bp) ph+ kml, prethodno liječenih jedan ili više inhibitora тирозинкиназы(s) [тки(e)] i za koga imatinib, nilotinib i dasatinib ne uzeti u obzir odgovarajuće mogućnosti liječenja .